Senior Correspondent, London
Ben's Feed
Dec 5, 2013
Dec 5, 2013

European drug trial secrecy case hit by delay

LONDON, Dec 5 (Reuters) – A legal case over access to
details of clinical trials held by Europe’s drugs regulator -
sparked by two U.S. firms wanting to keep their data secret -
has been hit by delay after the EU’s top court sent it back to
be re-examined by a lower body.

The decision leaves in limbo a high-profile fight that has
pitched the European Medicines Agency (EMA), Europe’s equivalent
of the U.S. Food and Drug Administration, against AbbVie
and InterMune.

Dec 5, 2013
Dec 4, 2013

Teva seeks deals to build drug portfolio, 2014 outlook next week

LONDON, Dec 4 (Reuters) – Israel’s Teva Pharmaceutical
Industries, the world’s biggest producer of generic
drugs, is looking to step up the pace of deal-making as it
braces for a slump in sales of top-selling multiple sclerosis
drug Copaxone.

“There is a lot of activity in building the pipeline and the
future portfolio,” Eyal Desheh, the company’s acting chief
executive, said on Wednesday.

Dec 3, 2013

Britain’s Cameron defends GSK’s business practices in China

SHANGHAI (Reuters) – British Prime Minister David Cameron on Tuesday mounted a robust defense of GlaxoSmithKline’s (GSK.L: Quote, Profile, Research, Stock Buzz) business practices in China – where it is being investigated for alleged bribery – calling the firm “very decent”.

Cameron’s intervention came a day after he raised GSK’s situation with China’s top leadership in a move one person familiar with the conversation said was designed to draw a line under the company’s woes and ensure it was treated fairly.

Dec 3, 2013

Cameron defends GSK’s business practices in China

SHANGHAI (Reuters) – British Prime Minister David Cameron on Tuesday mounted a robust defence of GlaxoSmithKline’s business practices in China – where it is being investigated for alleged bribery – calling the firm “very decent”.

Cameron’s intervention came a day after he raised GSK’s situation with China’s top leadership in a move one person familiar with the conversation said was designed to draw a line under the company’s woes and ensure it was treated fairly.

Dec 3, 2013
Dec 3, 2013

Analysis: Copycat biotech drugs slow to take off in Europe

LONDON (Reuters) – Despite austerity-driven cuts across European healthcare systems, most countries have been slow to embrace a new class of medicines that could save them billions of euros – copies of biotech treatments.

These cheaper versions of expensive biotech drugs, known as biosimilars, could slash the cost of treating diseases like cancer and rheumatoid arthritis in the same way that generics have curbed spending on traditional medicines.

Dec 3, 2013

Drug companies still struggling to improve R&D returns

LONDON, Dec 3 (Reuters) – The number of new drugs approved
for sale by regulators may be rising but manufacturers are still
struggling to get a decent bang for their research buck,
according to a report on Tuesday.

The global pharmaceuticals industry is trying to replenish
its medicine chest after a wave of patent expiries that peaked
in 2012. Optimism has been growing that the industry might have
been getting the formula right as more products, especially for
cancer and rare diseases, win approval.

Dec 2, 2013

Cameron raises GSK’s problems as CEO joins him on China visit

BEIJING/LONDON (Reuters) – British Prime Minister David Cameron raised GlaxoSmithKline’s (GSK.L: Quote, Profile, Research, Stock Buzz) problems in China – where it is being investigated for alleged bribery – with political leaders on Monday as the drugmaker emphasized its commitment to doing business there.

Cameron, who is visiting China with executives including GSK chief executive Andrew Witty, discussed the company’s dilemma with China’s leaders and stressed the need for a stable, predictable business environment, a person familiar with the matter said.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben